Literature DB >> 7500984

Simultaneous evaluation of dexamethasone-induced apoptosis and micronuclei in rat primary spleen cell cultures.

G Krishna1, G Urda, W Tefera, N D Lalwani, J Theiss.   

Abstract

Apoptosis or programmed cell death is a biological event that is biochemically and morphologically distinct from cellular necrosis. Nonetheless, its relationship has not been studied in terms of a cytogenetic endpoint such as micronucleus formation. In the present study, based on cytological observations, the incidence of dexamethasone-induced apoptotic cells was related to the frequency of micronucleated cells in vitro. Rat primary spleen cells were grown in 6-well plates with RPMI 1640 media using concanavalin A and lipopolysaccharide as mitogens. At culture initiation, the test agent dexamethasone (10, 20 or 40 microM) and a cytokinesis inhibitor cytochalasin B (3 micrograms/ml) were added. Cultures were harvested 18 h and 40 h later. Slides were prepared and stained with Diff-Quik stain. Frequencies of apoptotic cells and micronucleated binucleate cells were enumerated cytologically based on 500 cells per treatment from the same slides. The results showed a dose-dependent increase in the number of apoptotic cells in rat spleen cultures treated with dexamethasone. At 18 h, the percentages of apoptotic cells were 0.8, 1.6, 3.4 and 4.4 with 0, 10, 20 and 40 microM dexamethasone, respectively. The corresponding percentages of apoptotic cells at 40 h were: 2.8, 2.6, 5.6 and 10.4. However, at the same concentrations of dexamethasone, the micronucleus frequency in binucleate cells remained relatively unchanged. The phenomenon of apoptosis induced by dexamethasone was confirmed biochemically based on a characteristic DNA 'ladder' pattern by gel electrophoresis. These data suggest that dexamethasone at the concentrations which induced apoptosis did not produce cytogenetic damage. Also, these findings indicate that micronucleus formation and nuclear changes leading to apoptosis are separate events and these endpoints may not be closely correlated for dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500984     DOI: 10.1016/0027-5107(95)00075-3

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  5 in total

1.  Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay.

Authors:  Steven M Bryce; Derek T Bernacki; Jeffrey C Bemis; Richard A Spellman; Maria E Engel; Maik Schuler; Elisabeth Lorge; Pekka T Heikkinen; Ulrike Hemmann; Véronique Thybaud; Sabrina Wilde; Nina Queisser; Andreas Sutter; Andreas Zeller; Melanie Guérard; David Kirkland; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-04       Impact factor: 3.216

2.  Biomarkers of DNA damage response improve in vitro micronucleus assays by revealing genotoxic mode of action and reducing the occurrence of irrelevant positive results.

Authors:  Svetlana Avlasevich; Tina Pellegrin; Manali Godse; Steven Bryce; Jeffrey Bemis; Peter Bajorski; Stephen Dertinger
Journal:  Mutagenesis       Date:  2021-11-29       Impact factor: 3.000

3.  Predictions of genotoxic potential, mode of action, molecular targets, and potency via a tiered multiflow® assay data analysis strategy.

Authors:  Stephen D Dertinger; Andrew R Kraynak; Ryan P Wheeldon; Derek T Bernacki; Steven M Bryce; Nikki Hall; Jeffrey C Bemis; Sheila M Galloway; Patricia A Escobar; George E Johnson
Journal:  Environ Mol Mutagen       Date:  2019-02-27       Impact factor: 3.216

4.  γH2AX and p53 responses in TK6 cells discriminate promutagens and nongenotoxicants in the presence of rat liver S9.

Authors:  Derek T Bernacki; Steven M Bryce; Jeffrey C Bemis; David Kirkland; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2016-07-01       Impact factor: 3.216

5.  Genotoxic mode of action predictions from a multiplexed flow cytometric assay and a machine learning approach.

Authors:  Steven M Bryce; Derek T Bernacki; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2016-01-13       Impact factor: 3.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.